Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CLK1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CLK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CLK1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CLK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CLK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CLK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CLK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CLK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961521 | Oral cavity | EOLP | response to virus | 81/2218 | 367/18723 | 1.71e-08 | 7.66e-07 | 81 |
GO:001604924 | Oral cavity | EOLP | cell growth | 97/2218 | 482/18723 | 9.06e-08 | 3.15e-06 | 97 |
GO:001821015 | Oral cavity | EOLP | peptidyl-threonine modification | 35/2218 | 125/18723 | 7.33e-07 | 1.85e-05 | 35 |
GO:001810715 | Oral cavity | EOLP | peptidyl-threonine phosphorylation | 33/2218 | 116/18723 | 1.02e-06 | 2.51e-05 | 33 |
GO:001635815 | Oral cavity | EOLP | dendrite development | 55/2218 | 243/18723 | 1.43e-06 | 3.42e-05 | 55 |
GO:004677713 | Oral cavity | EOLP | protein autophosphorylation | 49/2218 | 227/18723 | 2.04e-05 | 3.21e-04 | 49 |
GO:004858815 | Oral cavity | EOLP | developmental cell growth | 49/2218 | 234/18723 | 4.67e-05 | 6.20e-04 | 49 |
GO:00488137 | Oral cavity | EOLP | dendrite morphogenesis | 34/2218 | 146/18723 | 7.56e-05 | 9.19e-04 | 34 |
GO:00309005 | Oral cavity | EOLP | forebrain development | 68/2218 | 379/18723 | 2.97e-04 | 2.79e-03 | 68 |
GO:001619722 | Oral cavity | EOLP | endosomal transport | 45/2218 | 230/18723 | 4.63e-04 | 4.07e-03 | 45 |
GO:190018021 | Oral cavity | EOLP | regulation of protein localization to nucleus | 30/2218 | 136/18723 | 5.23e-04 | 4.52e-03 | 30 |
GO:004867515 | Oral cavity | EOLP | axon extension | 27/2218 | 120/18723 | 7.04e-04 | 5.78e-03 | 27 |
GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
GO:00181081 | Oral cavity | EOLP | peptidyl-tyrosine phosphorylation | 64/2218 | 375/18723 | 1.65e-03 | 1.09e-02 | 64 |
GO:00219554 | Oral cavity | EOLP | central nervous system neuron axonogenesis | 11/2218 | 35/18723 | 1.74e-03 | 1.14e-02 | 11 |
GO:199013815 | Oral cavity | EOLP | neuron projection extension | 34/2218 | 172/18723 | 1.80e-03 | 1.17e-02 | 34 |
GO:190382821 | Oral cavity | EOLP | negative regulation of cellular protein localization | 25/2218 | 117/18723 | 2.33e-03 | 1.43e-02 | 25 |
GO:00219542 | Oral cavity | EOLP | central nervous system neuron development | 19/2218 | 81/18723 | 2.49e-03 | 1.52e-02 | 19 |
GO:006056015 | Oral cavity | EOLP | developmental growth involved in morphogenesis | 41/2218 | 234/18723 | 6.54e-03 | 3.21e-02 | 41 |
GO:000740910 | Oral cavity | EOLP | axonogenesis | 66/2218 | 418/18723 | 8.99e-03 | 4.13e-02 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLK1 | SNV | Missense_Mutation | | c.247N>C | p.Asn83His | p.N83H | P49759 | protein_coding | deleterious_low_confidence(0) | benign(0.047) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
CLK1 | SNV | Missense_Mutation | | c.246N>T | p.Glu82Asp | p.E82D | P49759 | protein_coding | deleterious_low_confidence(0.03) | benign(0.003) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
CLK1 | SNV | Missense_Mutation | | c.436T>G | p.Ser146Ala | p.S146A | P49759 | protein_coding | tolerated(0.05) | probably_damaging(0.977) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CLK1 | SNV | Missense_Mutation | | c.937N>G | p.Gln313Glu | p.Q313E | P49759 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLK1 | SNV | Missense_Mutation | | c.157G>C | p.Asp53His | p.D53H | P49759 | protein_coding | deleterious_low_confidence(0.02) | benign(0.024) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CLK1 | SNV | Missense_Mutation | rs758189196 | c.1037N>T | p.Ala346Val | p.A346V | P49759 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CLK1 | SNV | Missense_Mutation | | c.605N>C | p.Arg202Thr | p.R202T | P49759 | protein_coding | deleterious(0.01) | possibly_damaging(0.58) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CLK1 | SNV | Missense_Mutation | | c.737N>A | p.Arg246His | p.R246H | P49759 | protein_coding | tolerated(0.14) | benign(0.023) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
CLK1 | SNV | Missense_Mutation | novel | c.552G>T | p.Glu184Asp | p.E184D | P49759 | protein_coding | tolerated(0.05) | benign(0.337) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLK1 | SNV | Missense_Mutation | | c.974A>C | p.Lys325Thr | p.K325T | P49759 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565795 | | |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565842 | | |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | HARMINE | HARMINE | 22998443 |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565735 | | |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565841 | | |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | LEUCETTAMINE B | LEUCETTAMINE B | 22998443 |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | NU-2058 | CHEMBL269881 | |
1195 | CLK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | TG003 | | |